Literature DB >> 32016367

Understanding the use of observational and randomized data in cardiovascular medicine.

Louise Bowman1, Aris Baras2, René Bombien3, Robert M Califf4, Zhengmin Chen1, Chris P Gale5, J Michael Gaziano6, Diederick E Grobbee7, Aldo P Maggioni8,9, Evan D Muse10, Dan M Roden11,12,13, Stefan Schroeder14, Lars Wallentin15, Barbara Casadei16.   

Abstract

The availability of large datasets from multiple sources [e.g. registries, biobanks, electronic health records (EHRs), claims or billing databases, implantable devices, wearable sensors, and mobile apps], coupled with advances in computing and analytic technologies, have provided new opportunities for conducting innovative health research. Equally, improved digital access to health information has facilitated the conduct of efficient randomized controlled trials (RCTs) upon which clinical management decisions can be based, for instance, by permitting the identification of eligible patients for recruitment and/or linkage for follow-up via their EHRs. Given these advances in cardiovascular data science and the complexities they behold, it is important that health professionals have clarity on the appropriate use and interpretation of observational, so-called 'real-world', and randomized data in cardiovascular medicine. The Cardiovascular Roundtable of the European Society of Cardiology (ESC) held a workshop to explore the future of RCTs and the current and emerging opportunities for gathering and exploiting complex observational datasets in cardiovascular research. The aim of this article is to provide a perspective on the appropriate use of randomized and observational data and to outline the ESC plans for supporting the collection and availability of clinical data to monitor and improve the quality of care of patients with cardiovascular disease in Europe and provide an infrastructure for undertaking pragmatic RCTs. Moreover, the ESC continues to campaign for greater engagement amongst regulators, industry, patients, and health professionals in the development and application of a more efficient regulatory framework that is able to take maximal advantage of new opportunities for improving the design and efficiency of observational studies and RCT in patients with cardiovascular disease. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Big data; Electronic health records; Large prospective cohorts; Observational studies; Randomized clinical trials

Mesh:

Year:  2020        PMID: 32016367     DOI: 10.1093/eurheartj/ehaa020

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

1.  Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases.

Authors:  Willemien J Kruik-Kollöffel; Job van der Palen; Carine J M Doggen; Marissa C van Maaren; H Joost Kruik; Edith M Heintjes; Kris L L Movig; Gerard C M Linssen
Journal:  PLoS One       Date:  2020-12-22       Impact factor: 3.240

2.  Integrating sex and gender in studies of cardiac resynchronization therapy: a systematic review.

Authors:  Omar Dewidar; Irina Podinic; Victoria Barbeau; Dilan Patel; Alba Antequera; David Birnie; Vivian Welch; George A Wells
Journal:  ESC Heart Fail       Date:  2021-11-24

Review 3.  Sex Differences in Implantation and Outcomes of Cardiac Resynchronization Therapy in Real-World Settings: A Systematic Review of Cohort Studies.

Authors:  Omar Dewidar; Haben Dawit; Victoria Barbeau; David Birnie; Vivian Welch; George A Wells
Journal:  CJC Open       Date:  2021-09-09

Review 4.  Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart).

Authors:  Gorav Batra; Suleman Aktaa; Lars Wallentin; Aldo P Maggioni; Peter Ludman; David Erlinge; Barbara Casadei; Chris P Gale
Journal:  Eur Heart J       Date:  2022-06-21       Impact factor: 35.855

5.  Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).

Authors:  Suleman Aktaa; Gorav Batra; John G F Cleland; Andrew Coats; Lars H Lund; Theresa McDonagh; Giuseppe Rosano; Petar Seferovic; Peter Vasko; Lars Wallentin; Aldo P Maggioni; Barbara Casadei; Chris P Gale
Journal:  Eur Heart J       Date:  2022-06-14       Impact factor: 35.855

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.